- 1 Validation and clinical evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test
- 2 (sVNT)

3

7

10

- 4 Benjamin Meyer^{#,1}, Johan Reimerink^{#,2}, Giulia Torriani³, Fion Brouwer², Gert-Jan Godeke²,
- 5 Sabine Yerly⁴, Marieke Hoogerwerf², Nicolas Vuilleumier^{5,6}, Laurent Kaiser^{4,7,8}, Isabella
- 6 Eckerle^{#,*,3,7,8}, Chantal Reusken^{#,*,2}
- 8 #contributed equally
- 9 *corresponding authors
- 11 Affiliations:
- 12 ¹Centre for Vaccinology, Department of Pathology and Immunology, University of Geneva,
- 13 Geneva, Switzerland
- 14 ²Centre for Infectious Disease Control, WHO COVID-19 reference laboratory, RIVM, Bilthoven,
- 15 the Netherlands
- 16 ³Department of Microbiology and Molecular Medicine, University of Geneva, Geneva,
- 17 Switzerland
- 18 ⁴Laboratory of Virology, Geneva University Hospitals, Geneva, Switzerland
- 19 ⁵Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and
- 20 Geneva University, Geneva, Switzerland
- 21 ⁶Division of Laboratory Medicine, Department of Medicine, Faculty of Medicine, Geneva,
- 22 Switzerland
- 23 ⁷Division of Infectious Disease, Geneva University Hospitals, Geneva, Switzerland
- 24 ⁸Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva,
- 25 Switzerland

26

30

33

- 27 Address for correspondence:
- 28 Chantal Reusken: chantal.reusken@rivm.nl
- 29 Isabella Eckerle: Isabella.Eckerle@hcuge.ch
- 31 **Keywords:** SARS-CoV-2, neutralizing antibodies, surrogate virus neutralisation assay,
- 32 pseudovirus neutralisation assay, cell-based virus neutralisation assay
- 34 **Word count:**3519

Abstract

35

50

51

52

53

55 56

36 To understand SARS-CoV-2 immunity after natural infection or vaccination, functional assays

37 such as virus neutralizing assays are needed. So far, assays to determine SARS-CoV-2

38 neutralizing antibodies rely on cell-culture based infection assays either using wild type SARS-

39 CoV-2 or pseudotyped viruses. Such assays are labour-intensive, require appropriate biosafety

40 facilities and are difficult to standardize.

41 Recently, a new surrogate virus neutralisation assay (sVNT) was described that uses the principle

42 of an ELISA to measure the neutralization capacity of anti-SARS-CoV-2 antibodies directed

43 against the receptor binding domain.

Here, we performed an independent evaluation of the robustness, specificity and sensitivity on an

45 extensive panel of sera from 269 PCR-confirmed COVID-19 cases and 259 unmatched samples

46 collected before 2020 and compared it to cell-based neutralization assays.

We found a high specificity of 99.2 (95%CI: 96.9-99.9) and overall sensitivity of 80.3 (95%CI:

48 74.9-84.8) for the sVNT. Clinical sensitivity increased between early (<14 days post symptom

onset or post diagnosis, dpos/dpd) and late sera (>14 dpos/dpd) from 75.0 (64.7-83.2) to 83.1

(76.5-88.1). Also, higher severity was associated with an increase in clinical sensitivity. Upon

comparison with cell-based neutralisation assays we determined an analytical sensitivity of 74.3

(56.4-86.9) and 98.2 (89.4-99.9) for titres ≥10 to <40 and ≥40 to <160, respectively. Only samples

with a titre ≥160 were always positive in the sVNT.

In conclusion, the sVNT can be used as an additional assay to determine the immune status of

COVID-19 infected of vaccinated individuals but its value needs to be assessed for the specific

context of use.

Introduction

57

58

59 60

61

62

63

64

65 66

67

68

69

70

71

72

73

74

75

76 77

78

79

80

81

82

83

84 85

86 87

88 89

90

In 2020, the world is facing an unprecedented global health crisis through the emergence of the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the disease COVID-19. The pandemic spread of this virus immediately raised a demand for serological assays to support clinical and public health management, e.g. to determine a recent or past infection, to assess the level of (sub) population exposure and, to investigate different types of immune response and levels of potential immunity against re-infection. Seven months into the outbreak a plethora of serological assays is available 1 that allows the routine detection of several classes of antibodies, i.e. IgM, IgG and IgA²⁻⁵. However, to understand immunity after natural infection or vaccination, a functional analysis of the elicited antibody responses, such as avidity for the most immunogenic viral antigens and virus neutralizing activity, is of utmost importance⁶. So far, assays to determine SARS-CoV-2 neutralizing capability of antibodies rely on handling of wild type or pseudotyped viruses and use cell-culture based infection as a read-out. This requires a biosafety level (BSL) 3 laboratory for wild type SARS-CoV-2, or a BSL-2 laboratory for pseudotyped viruses such as vesicular stomatitis virus (VSV) or lentivirus-based systems. These in-house assays are difficult to standardize across laboratories, especially in the absence of an international standard, as assay characteristics vary depending on culture conditions, virus strains and cell lines used. Furthermore, these assays are labour-intensive, require highly skilled personnel, have a low throughput and results are only available after several days. Recently, a first commercial assay has become available⁷ that indirectly and semi- quantitatively measures the neutralizing functionality of SARS-CoV-2 antibodies while overcoming the above limitations. During natural infection, SARS-CoV-2 binds to its cellular receptor, the angiotensinconverting enzyme 2 (ACE2), via the receptor binding domain (RBD) of the viral spike (S) glycoprotein, which is an essential step to establish infection of the cell^{8,9}. The majority, but not all, of the neutralising antibodies are directed against the RBD leading to an inhibition of this interaction⁶. The assay detects SARS-CoV-2 antibodies that competitively inhibit the interaction between recombinant RBD-HRP fusion protein and recombinant ACE2 that is coated on 96-well plates. The assay is independent of the use of replicating or pseudotyped virus and cell cultures and uses the same format/set-up as Enzyme-Linked Immunosorbent Assays (ELISA), allowing for high-throughput, automation and fast turnaround times. Here, we present an independent, two-centre evaluation of the robustness, specificity and sensitivity of a commercially available version of this novel functional immune-assay based on an

extensive panel of sera from a) a heterogeneous cohort of PCR-confirmed COVID-19 patients, b)

pre-outbreak syndromic patients with respiratory complaints including confirmed recent infections with the four common human coronaviruses (HCoV) and c) pre-outbreak population sera. The assay performance was evaluated against the conventional cell culture-based wildtype SARS-CoV-2 (Gold Standard method) and VSV-based pseudo-type neutralization assays to assess its value to measure levels of functional antibodies directed against SARS-CoV-2.

Material and Methods

Sample collection

RIVM: sera from common CoV cases and non-CoV respiratory cases were partially obtained from a previous study approved by the ethics committee of the National Institute of Public Health and the Environment (METC Noord-Holland, http://www.trialregister.nl; NTR3386 and 4818¹⁰ and partially from anonymized leftover serum from routine diagnostics for respiratory pathogens or SARS-CoV-2 for which ethical approval was waived by the ethics committees of Brabant and Utrecht (NW2020-31 and NL13529.041.06; 06/282). The current study was performed in accordance with the guidelines for sharing of patient data of observational scientific research in emergency situations as issued by the Commission on Codes of Conduct of the Federation of Dutch Medical Scientific Societies (https://www.federa.org/federa-english).

University of Geneva/HUG: Anonymized leftovers of serum and plasma samples were used for this analysis. Ethical approval for all samples used in this study was waived by the local ethics committee of the HUG that approves usage of leftover of patient samples collected for diagnostic purposes in accordance with our institutional and national regulations.

The study included blood samples from 269 real-time (RT)-PCR confirmed COVID-19 cases (sensitivity panel) and 259 unmatched samples collected before 2020 (specificity panel). We used days post onset of symptoms (dpos) in cases where the onset was known or days post PCR diagnosis (dpd) if the onset was unknown. Samples were stored at -20°C and thawed immediately before the assay was performed. The specificity panel included sera collected before 2020 from healthy blood donors (n=100), patients with other respiratory diseases including (i) a two months earlier PCR-confirmed common HCoV infection, HCoV-229E (n=12), HCoV-NL63 (n=10), HCoV-HKU1 (n=6) or HCoV-OC43 (n=10)¹⁰, (ii) patients with a recent PCR-confirmed non-CoV respiratory infection (n=14) i.e. Influenza A virus (n=3), human metapneumovirus (HMPV) (n=4), respiratory syncytial virus (RSV) B (n=1), RSV A + HMPV (n=1), hemophilus influenza (n=1), mycoplasma pneumonia (n=1) and rhinovirus (n=3). Further it included patients with respiratory complaints that tested negative for a suspected *Bordetella pertussis* infection (n=16), patients with an acute cytomegalovirus (n=10) or acute Epstein-Barr virus (n=10) infection as well as adult

(n=21) and child (n=50) patients who came for routine diagnostic purposes to the hospital (Table 1). The sensitivity panel included sera from 269 PCR-confirmed COVID-19 patients. Of these sera, 92 were taken before and 177 after 14 dpos/dpd. Severity of disease ranged from asymptomatic (n=3) to mild (non-hospitalized, n=92), severe (hospitalized, n=87) and ICU-admitted/deceased (hospitalized, n=54). For 33 patients the severity of disease was unknown (Table 1).

Surrogate SARS-CoV-2 Virus Neutralisation Test

The surrogate virus neutralisation test (sVNT) (GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit, Genscript, The Netherlands) was performed according to the manufacturer's instructions. Both laboratories used the same LOT number (20E012157). Briefly, serum samples as well as positive and negative assay controls were diluted 1:10 in sample dilution buffer and mixed with an equal volume of HRP-conjugated RBD. Controls were tested in duplicates and samples in singular. After a 30 minute incubation at 37 °C, 100 µl of this mixture was transferred to a 96-well plate coated with recombinant ACE2. After incubation at 37 °C for 15 minutes, the supernatant was removed and the plate was washed 4x using the provided wash buffer. 100 µl TMB substrate was added and incubated for 15 minutes at room temperature before the reaction was stopped by addition of 50 µl stop solution. Plates were read at 450 nm immediately afterwards. Percentage reduction (%reduction) for each sample was calculated by using the following formula:

$$%reduction = (1 - \frac{OD450 (sample)}{Average OD450 (neg. ctrl.)}) \times 100$$

VSV-based Pseudovirus Neutralisation Test (PNT₅₀)

The VSV-based pseudovirus neutralisation test, was done as described previously². Briefly, African green monkey (VeroE6) cells were seeded in 96-well plates at 2 x 10⁴ cells per well and grown into confluent monolayer overnight. Sera from patients were inactivated at 56°C for 30 minutes and diluted from 1:5 to 1:1280 in DMEM 2% fetal bovinve serum (FBS). VSV-based SARS-CoV-2 pseudotypes (generated according to Berger, Rentsch, and Zimmer¹¹ and Torriani et al.¹² expressing a 19 amino acids C-terminal truncated spike protein¹³ (NCBI Reference sequence: NC_045512.2) were diluted in DMEM 2% FBS in order to have MOI=0.01 per well and added on top of serum dilutions (final serum dilutions obtained were from 1:10 to 1:2560). The virus-serum mix was incubated at 37°C, for 2h. Vero E6 were then infected with 100µl of virus-serum mixtures. After incubation at 37°C for 1.5h, cells were washed once with 1X PBS and

DMEM 10% FBS was added. After 16-20h of incubation at 37°C, 5% CO₂ cells were fixed with 4% formaldehyde solution for 15min at 37°C and nuclei stained with 1µg/ml DAPI solution. GFP positive infected cells were counted with ImageXpress® Micro Widefield High Content Screening System (Molecular Devices) and data analyzed with MetaXpress 5.1.0.41 software.

SARS-CoV-2 Virus Neutralisation Test

SARS-CoV-2 virus neutralization tests were performed exactly as described ¹⁴. Two-fold serial dilutions (starting at 1:10) of heat-inactivated sera (30 min, 56°C) were incubated in duplicate with 100 TCID₅₀ of SARS-CoV-2 strain HCoV-19/Netherlands/ZuidHolland_10004/2020 (EVAg cat.nr. 014V-03968) at 35°C, 5% CO₂ for 1 h in 96-wells plates. Vero-E6 cells were added in a concentration of 2 x 10⁴ cells per well and incubated for three days at 35°C in an incubator with 5% CO₂. The serum virus neutralization titre (VNT₅₀) was defined as the reciprocal value of the sample dilution that showed a 50 % protection of virus growth. Samples with titres \geq 10 were defined as SARS-CoV-2 seropositive.

Wantai SARS-CoV-2 total antibody Assay

The Wantai SARS-CoV-2 total antibody ELISA (Beijing Wantai Biological Pharmacy Enterprise, Beijing, China; catalogue number WS1096) was performed exactly according to the manufacturer's instructions³. This assay is a double-antigen sandwich ELISA using a recombinant RBD of SARS-CoV-2 as antigen. Optical density (OD) is measured at 450 nm and the antibody titre for each sample is calculated as the ratio of the reading of that sample to the reading of a calibrator (included in the kit): OD ratio.

Statistical analysis

Statistical analysis was performed with GraphPad Prism version 8.4.3 using Mann-Whitney or Kruskal-Wallis test with Dunn's multiple comparison test where appropriate. Linear regression was also performed using GraphPad Prism version 8.4.3. Calculation of sensitivity, specificity and 95% confidence intervals (95%CI) was done using the VassarStats statistical toolbox (http://www.vassarstats.net/). Results with p values <0.05 were considered significant.

Results

In this study, we validated an ELISA-based surrogate SARS-CoV-2neutralisation assay (sVNT) using specificity and sensitivity panels as described above. Among the 259 samples in the specificity panel we identified two samples, one among the blood donors and one in the cohort

with a recent non-CoV respiratory infection (HMPV infected) that were positive using the manufacturer recommended cut-off of 20% reduction (%reduction: 97.2 and 21.6, respectively). Both samples were tested in the VNT₅₀ and did not show any SARS-CoV-2 neutralising activity. Considering an alternative cut-off of 30% reduction, as proposed in a recent publication by the manufacturer⁷, only the blood donor sample remained positive for blocking RBD binding to ACE2 (Figure 1A). This indicates a specificity of 99.2 (95% CI: 96.9-99.9) and 99.6 (95% CI: 97.5-99.9), respectively (Table 2).

192

193

194

195

196

197

198

199200

201

202

203

204

205

206

207

208209

210

211

212

213

214

215

216

217

218

219

220221

222

223

224225

Among the 269 sera of confirmed COVID-19 patients in the sensitivity panel, 216 sera tested positive in the sVNT resulting in an overall clinical sensitivity of 80.3 (95%CI: 74.9-84.8). In sera sampled before 14 dpos/dpd 69/92 samples blocked RBD-ACE2 interaction (clinical sensitivity 75.0 (95%CI: 64.7-83.2) while 147/177 sera sampled at or after 14 dpos/dpd tested positive, resulting in an increased clinical sensitivity of 83.1 (95%CI: 76.5-88.1). In addition, median %reduction significantly increased between <14 and ≥14 dpos/dpd from 61.2% to 82.5% (Mann Whitney test, p=0.0019) (Figure 1B, 2A and Table 3). Furthermore, we analysed the relationship between the severity of COVID-19 disease and the clinical sensitivity of the sVNT as stronger immune responses were observed in severe vs mild cases^{14,15}. We observed that the assay sensitivity increased with an increased disease severity, higher in hospitalised patients vs outpatients, regardless of the time of sampling. During the acute phase (<14dpos/dpd) of the infection, the clinical sensitivity in mild cases was 47.4% and increased to 70.7% and 100% in severe and ICU/deceased patients, respectively (Figure 1D and Table 3). A similar observation was made in samples collected ≥14 dpos/dpd, where sensitivity increased from 75.3% in mild cases to 91.3% and 88.2% in severe and ICU/deceased cases, respectively (Figure 1E and Table 3). The median %reduction in the sVNT increased with disease severity, but this increase was only significant for mild vs severe and mild vs ICU/deceased cases both before and after 14dpos/dpd (Kruskal-Wallis test) (Figure 1D and E). When considering the alternative cut-off of 30% reduction to determine positivity in the sVNT, the clinical sensitivity of the assay decreased by 0-9%, but the overall picture remained unchanged (Table 3).

As the novel assay is meant to be implemented as a surrogate assay for functional cell-based serological methods that measure SARS-CoV-2 neutralising capacity of antibodies, we compared the performance of the sVNT with the conventional VNT₅₀ and PNT₅₀ assays. The sVNT detected blocking of ACE2 binding activity in nine of 50 sera of confirmed COVID-19 patients that did not show SARS-CoV-2 neutralising activity in the cell-based assays (Table 3). Conversely, only 26/35

sera with a titre in the range of \geq 10 to <40 as well as 56/57 sera with a titre in the range of \geq 40 to <160 in the cell-based neutralisation assays showed blocking activity in the sVNT. This results in an analytical sensitivity of 74.3 (95% CI: 56.4-86.9) and 98.2 (95% CI: 89.4-99.9) respectively when compared to conventional in-house neutralisation assays. Only sera (n=116) with a titre of \geq 160 in the PNT₅₀/VNT₅₀ were always positive in the sVNT. The median %reduction in the four titre subgroups significantly increased with rising PNT₅₀/VNT₅₀ titres from -2.6 (<10) to 36.0 (\geq 10 to <40), 75.6 (\geq 40 to <160) and 92.5 (\geq 160) (Kruskal-Wallis test) (Figure 1C). To further investigate the correlation of PNT₅₀/VNT₅₀ titres with %reduction in the sVNT, a linear regression analysis was performed using all sera for which an endpoint titre was available (n=154). We found a moderate correlation between PNT₅₀ and sVNT %reduction (R²= 0.4937, p>0.0001) (Figure 2B) and a slightly better correlation for VNT₅₀ titres (R²= 0.6548, p>0.0001) (Figure 2C).

We also compared overall clinical sensitivity and specificity of the assay between the two centres where the study was conducted (UNIGE and RIVM). Specificity was comparable with only minor differences between the two laboratories. In contrast, clinical sensitivity was markedly lower at UNIGE compared to samples analysed at RIVM (Table 4). However, samples from late time points dpos/dpd where underrepresented in the UNIGE sample set, giving a potential explanation for this discrepancy.

Last, we investigated the interassay variance of the sVNT by testing a representative subset of samples at least five times at different days. Similar coefficients of variation (%CV) were found in both laboratories. We observed a very low %CV in samples with a mean %reduction > 90%, ranging from 0.22 to 4.63 %CV. However, the %CV increased to 3.55-13.73 in samples with a mean %reduction between 50-60% and to 10.39-20.39 in samples with a mean %reduction around 30%. Samples with a mean %reduction <11% gave a high %CV between 67.33-216.38 (Table 5).

Discussion

The importance of serology in clinical and public health management of SARS-CoV-2 is reflected in the huge amount of immune-assays that are currently being developed or have been released on the diagnostic market¹. However, a vast majority of these tests are simply measuring qualitatively or semi-quantitatively the presence of IgG, IgM and/or IgA but do not address the functionality of the antibody response elicited by a SARS-CoV-2 infection. Functional assays like virus neutralization tests are essential to address specific questions related to protective immunity

after vaccination or natural infection. However, these type of assays are operated based on inhouse protocols and lack standardization across laboratories^{16–18}. We performed an independent two-centre clinical evaluation of the GenScript cPass™ test, which is based on the principle of an inhibition ELISA, to assess its value for routine diagnostics and as surrogate functional assay to measure neutralizing capability in SARS-CoV-2 elicited antibody responses.

260

261 262

263

264

265 266

267

268

269

270

271

272

273

274

275

276

277

278 279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

We observed a high specificity of > 99% and an overall clinical sensitivity of 83% in samples taken ≥14 dpos. Within this group of confirmed COVID-19 patients, the clinical sensitivity was 75% in mild and 91% in hospitalized patients. Deeks and colleagues performed a Cochrane assessment of 54 studies using commercial immune-assays⁵. They concluded that in confirmed COVID-19 patients sampled in the periods 15-21 dpos and 22-25 dpos, the sensitivities for IgG were respectively 88.2% (95% CI 83.5 to 91.8) and 80.3% (95%CI 72.4 to 86.4). While direct comparison of performances of different serology assays is complicated by differences in test setup (e.g. testing for all isotypes vs for IgG only, the use of different antigens, measuring antigen binding vs prevention of RBD-ACE2 binding) and differences in patient cohorts used, our results seem to indicate that the sVNT might be a more powerful tool for cohort and population studies than for individual diagnosis of past SARS-CoV-2 infection as the observed sensitivities are in the lower end of the range of average test performances observed by Deeks.

With respect to the sVNT as alternative for conventional virus culture-based assays measuring neutralizing activity, we observed that on the one hand the sVNT misses samples that have a low virus neutralization titre in these assays and on the other hand identifies samples as positive that were negative in a Gold Standard tests. A limitation of the sVNT is the restriction to RBD binding antibodies. It has been shown that SARS-CoV-2 infection does not only induce antibodies against the RBD or the S1 domain, but also against the S2 domain as well as against N¹⁹. While antibodies directed against the N protein are most likely non-neutralizing, antibodies directed against the Nterminal domain of S1 (outside of the RBD) have shown neutralizing potential²⁰. In addition, for SARS-CoV-1 also antibodies directed at the S2 domain show neutralizing capabilities²¹. Although S2 domain-mediated neutralisation remains to be confirmed for SARS-CoV-2, assessing the neutralizing ability with the sVNT might indeed miss the presence of virus neutralizing capabilities directed outside of the RBD. Furthermore, all of the sera that were reactive in the sVNT but not in the VNT₅₀/PNT₅₀ were reactive in the Wantai total Ig ELISA that targets RBD as well (data not shown). This indicates that the activity measured in the sVNT is likely due to antibodies directed against the RBD but without a virus neutralising capacity that leads to at least 50% reduction of

infected cells. Another explanation for such false positivity with respect to neutralizing capability might be the presence of anti-ACE2 autoantibodies as described for specific patient groups^{22,23}. The observation of false positives and the observed lower sensitivity (74%) of the sVNT in comparison to conventional tests in samples with neutralizing antibody titres ≥10 and <40, indicate that the sVNT cannot fully replace the Gold Standard immune-assays. Depending on the context of use, the lower sensitivity in the range of low virus neutralization titres might however be acceptable, e.g. for decision making on release of hospitalized patients with virus neutralization titres above a predetermined threshold from isolation units^{24,25}. Nevertheless, as long as the correlates of protection for classical virus neutralization tests are not known, the use of the sVNT as functional assay to determine level of immunity is not warranted.

Besides the aforementioned advantages of the possibility for increased standardization across laboratories, the possibility for automatization, the technical simplicity and the reduced biosafety risk, the sVNT is isotype- and species-independent. Species-independent serology tools are important for research into the epidemiology and ecology of SARS-CoV-2, i.e. for the identification of natural reservoirs and spill-over hosts as well as the monitoring and prevention of human risks from sustained virus circulation in farm animals such as minks (refs). In contrast to virus culturebased assays, the sVNT is at most a semi-quantitative assay making it less valuable as functional assay in immunity studies.

In conclusion, the sVNT can be used as an additional assay to determine the immune status of COVID-19 infected of vaccinated individuals and cohort studies to confirm results of more routine immuno-assays like IgG, IgM and/or IgA ELISAs and CLIAs. The value of the sVNT as functional assay in patient management, biosafety management, vaccine and immunity studies needs to be assessed for the specific context of use.

Figure Legends:

294

295

296 297

298

299

300

301

302

303

304 305

306

307

308

309

310

311

312

313 314

315

316

317

318

319 320

321

322

323

324

325

Figure 1: %reduction (inhibition of RBD-ACE2 binding) of samples of the specificity panel). %reduction of PCR-confirmed COVID-19 patient samples stratified (A) by days post onset of symptoms (dpos) or days post diagnosis (dpd) (B), by results of PNT₅₀/VNT₅₀ titre (C) and by disease severity (**D** and **E**). Dashed line indicates 20% or 30% cut-off (CO).

- Figure 2: %reduction (inhibition of RBD-ACE2 binding) of COVID-19 patient samples by dpos/dpd
- and disease severity (A). Linear correlation of PNT₅₀ (B) and VNT₅₀ (C) endpoint titres with
- 328 %reduction of RBD-ACE2 binding. Dashed line indicates 20% or 30% cut-off (CO).
- 330 Acknowledgements: We would like to thank Romain Burguier (HUG, Geneva) for technical
- assistance and Barbara Lemaitre (HUG, Geneva) and Shefije Fejza (HUG, Geneva) for help with
- 332 sample preparation. We are grateful to Jean-Luc Murk (Elizabeth-Tweesteden Ziekenhuis,
- 333 Tilburg, the Netherlands), Afke Brandenburg (Izore, Leeuwarden, the Netherlands) and Bas
- 334 Wintermans (Admiraal de Ruyter Ziekenhuis, Goes, the Netherlands), Josine van Beek and
- 335 Kristin Kremer (RIVM) for provision of panel samples an Mariette Edema (RIVM) for support. This
- 336 study was support by a grant from the Private Foundation of the Geneva University Hospital.

Bibliography

329

337338

- 1. Foundation for Innovative New Diagnostics. FIND evaluation update: SARS-CoV-2
- immunoassays. FIND evaluation update: SARS-CoV-2 immunoassays
- https://www.finddx.org/covid-19/sarscov2-eval-immuno/ (2020).
- 342 2. Meyer, B. et al. Validation of a commercially available SARS-CoV-2 serological
- immunoassay. Clinical Microbiology and Infection S1198743X20303682 (2020)
- 344 doi:10.1016/j.cmi.2020.06.024.
- 345 3. Lassaunière, R. et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv
- 346 2020.04.09.20056325 (2020) doi:10.1101/2020.04.09.20056325.
- 4. GeurtsvanKessel, C. H. et al. An evaluation of COVID-19 serological assays informs future
- diagnostics and exposure assessment. *Nat Commun* **11**, 3436 (2020).
- 349 5. Deeks, J. J. et al. Antibody tests for identification of current and past infection with SARS-
- 350 CoV-2. Cochrane Database of Systematic Reviews (2020)
- 351 doi:10.1002/14651858.CD013652.
- 352 6. Barnes, C. O. et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal
- 353 Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842.e16 (2020).

- 354 7. Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test (sVNT) based on
- antibody-mediated blockage of ACE2-spike (RBD) protein-protein interaction. 355
- 356 https://www.researchsquare.com/article/rs-24574/v1 (2020) doi:10.21203/rs.3.rs-24574/v1.
- 357 8. Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
- 358 Science eabb2507 (2020) doi:10.1126/science.abb2507.
- 9. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 359
- 360 Blocked by a Clinically Proven Protease Inhibitor. Cell S0092867420302294 (2020)
- doi:10.1016/j.cell.2020.02.052. 361
- 362 10. van Beek, J. et al. Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination
- 363 in a Cohort of Older Adults, Despite Effectively Reducing Laboratory-Confirmed Influenza
- 364 Virus Infections. The Journal of Infectious Diseases 216, 415–424 (2017).
- 365 11. Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based bioassay for
- 366 the rapid and sensitive determination of multi-species type I interferon. PLoS ONE 6,
- 367 e25858 (2011).
- 368 12. Torriani, G. et al. Identification of Clotrimazole Derivatives as Specific Inhibitors of
- 369 Arenavirus Fusion. J. Virol. 93, (2019).
- 370 13. Fukushi, S. et al. Vesicular stomatitis virus pseudotyped with severe acute respiratory
- 371 syndrome coronavirus spike protein. J. Gen. Virol. 86, 2269–2274 (2005).
- 372 14. Rijkers, G. et al. Differences in Antibody Kinetics and Functionality Between Severe and
- 373 Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infections. The Journal of
- Infectious Diseases jiaa463 (2020) doi:10.1093/infdis/jiaa463. 374
- 375 15. Cervia, C. et al. Systemic and mucosal antibody secretion specific to SARS-CoV-2 during
- 376 mild versus severe COVID-19. http://biorxiv.org/lookup/doi/10.1101/2020.05.21.108308
- 377 (2020) doi:10.1101/2020.05.21.108308.
- 16. Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis 378
- 379 and vaccine evaluation. Nat Commun 11, 4059 (2020).

- 380 17. Zettl, F. et al. Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using
- 381 Propagation-Defective Vesicular Stomatitis Virus Pseudotypes. Vaccines 8, 386 (2020).
- 382 18. Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature
- 383 **581**, 465–469 (2020).
- 384 19. Grzelak, L. et al. A comparison of four serological assays for detecting anti-SARS-CoV-2
- 385 antibodies in human serum samples from different populations. Sci. Transl. Med. 12,
- 386 eabc3103 (2020).
- 20. Chi, X. et al. A neutralizing human antibody binds to the N-terminal domain of the Spike 387
- 388 protein of SARS-CoV-2. Science 369, 650-655 (2020).
- 389 21. Duan, J. et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein.
- 390 Biochem. Biophys. Res. Commun. 333, 186-193 (2005).
- 391 22. Takahashi, Y., Haga, S., Ishizaka, Y. & Mimori, A. Autoantibodies to angiotensin-converting
- 392 enzyme 2 in patients with connective tissue diseases. Arthritis Res Ther 12, R85 (2010).
- 393 23. McMillan, P., MB, BS, MRCP & Uhal, B. D., PhD. COVID-19-A theory of autoimmunity to
- 394 ACE-2. MOJ Immunology 7, 17-19 (2020).
- 395 24. Singanayagam, A. et al. Duration of infectiousness and correlation with RT-PCR cycle
- 396 threshold values in cases of COVID-19, England, January to May 2020. Eurosurveillance
- 397 **25**, (2020).

402

- 398 25. van Kampen, J. J. A. et al. Shedding of infectious virus in hospitalized patients with
- 399 coronavirus disease-2019 (COVID-19): duration and key determinants.
- 400 http://medrxiv.org/lookup/doi/10.1101/2020.06.08.20125310 (2020)
- 401 doi:10.1101/2020.06.08.20125310.

Figure 1






Figure 2








Table 1: Demographics

		•	•		Sex	
Cohort	N	Collection year	Age range	Female	Male	Unknown
Pre-pandemic samples	259					
Adult patients	21	2018	25-71	15	6	0
Child patients	50	2018	1-11	24	26	0
CMV	10	2016	Unknown	0	0	10
EBV	10	2016	Unknown	0	0	10
Suspected Pertussis	16	2019	<18	0	0	16
Other Resp. Diseases	52	2011-2015	>60	0	0	52
Blood Donors	100	2016	18-79	0	0	100
PCR-confirmed COVID-19 patients	269	2020	24-91	66	136	67
<14 dpos/dpd	92		24-88	22	59	11
≥14 dpos/dpd	177		24-91	44	77	56
Severity						
Asymptomatic	3		57-71	0	3	0
Mild	92		24-91	29	31	32
Severe	87		42-88	24	49	14
ICU/Deceased	54		56-87	8	29	17
unknown	33		37-83	5	24	4

Table 2: Specificity of sVNT

			20% Cut-off	:	30% Cut-off				
Category	Total (n)	Positive (%)	Negative (%)	Specificity (95% CI)	Positive (%)	Negative (%)	Specificity (95% CI)		
Pre-pandemic adult patients	21	0 (0)	21 (100)	100 (80.8-100)	0 (0)	21 (100)	100 (80.8-100)		
Pre-pandemic child patients	50	0 (0)	50 (100)	100 (91.1-100)	0 (0)	50 (100)	100 (91.1-100)		
CMV	10	0 (0)	10 (100)	100 (65.5-100)	0 (0)	10 (100)	100 (65.5-100)		
EBV	10	0 (0)	10 (100)	100 (65.5-100)	0 (0)	10 (100)	100 (65.5-100)		
Suspected Pertussis	16	0 (0)	16 (100)	100 (75.9-100)	0 (0)	16 (100)	100 (75.9-100)		
Other Resp. Diseases	52	1 (1.9)	51 (98.1)	98.1 (88.4-99.9)	0 (0)	52 (100)	100 (91.4-100)		
Blood Donors	100	1 (1.0)	99 (99.0)	99.0 (93.8-99.9)	1 (1.0)	99 (99.0)	99.0 (93.8-99.9)		
Total	259	2 (0.8)	257 (99.2)	99.2 (96.9-99.9)	1 (0.4)	257 (99.6)	99.6 (97.5-99.9)		

CMV, cytomegalovirus; EBV, Epstein-Barr virus; ILI, influenza like illness; 95% CI, 95% confidence interval

Table 3: Sensitivity of sVNT

		20% Cut-off			30% Cut-off			
Category Total		Positive (%)	Negative (%)	Sensitivity % (95% CI)	Positive (%)	Negative (%)	Sensitivity % (95% CI)	
All	269	216 (80.3)	53 (19.7)	80.3 (74.9-84.8)	207 (77.0)	62 (23.0)	77.0 (71.4-81.8)	
dpos/dpd								
<14 days	92	69 (75.0)	23 (25.0)	75.0 (64.7-83.2)	68 (73.9)	24 (26.1)	73.9 (63.5-82.3)	
≥14 days	177	147 (83.1)	30 (16.9)	83.1 (76.5-88.1)	139 (78.5)	38 (21.5)	78.5 (71.6-84.2)	
P-NT50/VNT50								
<10	50	9 (18.0)	41 (82.0)	18.0 (9.0-31.9)	6 (12.0)	44 (88.0)	12.0 (5.0-25.0)	
≥10 to <40	35	26 (74.3)	9 (25.7)	74.3 (56.4-86.9)	24 (68.6)	11 (31.4)	68.6 (50.6-82.6)	
≥40 to <160	57	56 (98.2)	1 (1.8)	98.2 (89.4-99.9)	55 (96.3)	2 (3.7)	96.3 (86.2-99.4)	
≥160	116	116 (100)	0 (0)	100 (96.0-100)	115 (99.1)	1 (0.9)	99.1 (94.6-100)	
ND	11	9 (81.8)	2 (18.2)	81.8 (47.8-96.8)	7 (63.6)	4 (36.4)	63.6 (31.6-87.6)	
Severity <14 dpos/dp	od							
Mild	19	9 (47.4)	10 (52.6)	47.4 (25.2-70.5)	9 (47.4)	10 (52.6)	47.4 (25.2-70.5)	
Severe	41	29 (70.7)	12 (29.3)	70.7 (54.3-83.4)	29 (70.7)	12 (29.3)	70.7 (54.3-83.4)	
Deceased	20	20 (100)	0 (0)	100 (80.0-100)	20 (100)	0 (0)	100 (80.0-100)	
unknown	12	11 (91.7)	1 (8.3)	91.7 (59.8-99.6)	10 (83.3)	2 (16.7)	83.3 (50.9-97.1)	
Severity ≥14 dpos/dp	od							
Asymptomatic	3	2 (66.7)	1 (33.3)	66.7 (12.5-98.2)	2 (66.7)	1 (33.3)	66.7 (12.5-98.2)	
Mild	73	55 (75.3)	18 (24.7)	75.3 (63.6-84.4)	50 (68.5)	23 (31.5)	68.5 (56.4-78.6)	
Severe	46	42 (91.3)	4 (8.7)	91.3 (78.3-97.2)	41 (89.1)	5 (10.9)	89.1 (75.6-95.9)	
ICU/Deceased	34	30 (88.2)	4 (11.8)	88.2 (71.6-96.2)	30 (88.2)	4 (11.8)	88.2 (71.6-96.2)	
unknown	21	18 (85.7)	3 (14.3)	85.7 (62.6-96.2)	16 (76.2)	5 (23.8)	76.2 (52.5-90.9)	

DPOS, days post onset of symptoms; DPD days post diagnosis; P-NT50 pseudovirus neutralization test 50% inhibition titer; VNT50 virus neutralization test 50% inhibition titer; ND, not determined; 95% CI, 95% confidence interval

Table 4: Comparison of sVNT between sites

	UN	NIGE	RIVM		
	20% Cut-off	30% Cut-off	20% Cut-off	30% Cut-off	
Overall Specificity (95% CI)	100 (93.6-100)	100 (93.6-100)	98.9 (95.8-99.8)	99.5 (96.6-99.9)	
Overall Sensitivity (95% CI)	70.9 (56.9-81.9)	63.6 (49.5-75.8)	82.7 (76.8-87.4)	80.4 (74.3-85.3)	

95% CI, 95% confidence interval

Table 5: Interassay variance of sVNT

		UNIGE			RIVM					
Sample	No. of repeats	Mean % reduction	SD	% CV	Sample	No. of repeats	Mean % reduction	SD	% CV	
					001	5	-4.35	3.30	75.82	
					002	5	4.10	8.87	216.39	
49_neg_2018	5	7.70	5.18	67.33	003	5	10.28	9.09	88.45	
30193717	5	30.21	3.14	10.39	004	5	31.66	6.46	20.39	
					005	5	32.75	5.00	15.25	
30189617	5	57.29	2.03	3.55	006	5	53.76	7.38	13.73	
				007	5	54.89	2.47	4.50		
					800	5	92.38	4.28	4.63	
30175147	5	96.30	0.21	0.22	009	5	93.71	2.63	2.80	

SD, standard deviation; CV, coefficient of variation